DK4081246T3 - Sammensætning til behandling eller forebyggelse af en allergi eller allergisk reaktion - Google Patents

Sammensætning til behandling eller forebyggelse af en allergi eller allergisk reaktion Download PDF

Info

Publication number
DK4081246T3
DK4081246T3 DK20839094.8T DK20839094T DK4081246T3 DK 4081246 T3 DK4081246 T3 DK 4081246T3 DK 20839094 T DK20839094 T DK 20839094T DK 4081246 T3 DK4081246 T3 DK 4081246T3
Authority
DK
Denmark
Prior art keywords
allergy
prevention
treatment
composition
allergic reaction
Prior art date
Application number
DK20839094.8T
Other languages
English (en)
Inventor
Henrik Jan Ankersmit
Michael Mildner
Original Assignee
Aposcience Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aposcience Ag filed Critical Aposcience Ag
Application granted granted Critical
Publication of DK4081246T3 publication Critical patent/DK4081246T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/48—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
    • C12N2529/10—Stimulation by light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK20839094.8T 2019-12-23 2020-12-23 Sammensætning til behandling eller forebyggelse af en allergi eller allergisk reaktion DK4081246T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19219342.3A EP3842064A1 (en) 2019-12-23 2019-12-23 Composition for treating or preventing an allergy or allergic reaction
PCT/EP2020/087757 WO2021130305A1 (en) 2019-12-23 2020-12-23 Composition for treating or preventing an allergy or allergic reaction

Publications (1)

Publication Number Publication Date
DK4081246T3 true DK4081246T3 (da) 2024-06-10

Family

ID=69061128

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20839094.8T DK4081246T3 (da) 2019-12-23 2020-12-23 Sammensætning til behandling eller forebyggelse af en allergi eller allergisk reaktion

Country Status (13)

Country Link
US (1) US20230000910A1 (da)
EP (2) EP3842064A1 (da)
JP (1) JP7675446B2 (da)
KR (1) KR102996956B1 (da)
CN (1) CN115023235B (da)
AU (1) AU2020415329A1 (da)
BR (1) BR112022011976A2 (da)
CA (1) CA3161094A1 (da)
DK (1) DK4081246T3 (da)
ES (1) ES2982055T3 (da)
HU (1) HUE066648T2 (da)
PL (1) PL4081246T3 (da)
WO (1) WO2021130305A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4197547A1 (en) * 2021-12-20 2023-06-21 Aposcience AG Composition for treating or preventing vasculitis and diseases associated with vasculitis
US20240303638A1 (en) * 2023-03-08 2024-09-12 Capital One Services, Llc Systems and methods for secure authentication of contactless card

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2201954A1 (en) 2008-12-18 2010-06-30 Aposcience AG Pharmaceutical preparation
EP2198873A1 (en) 2008-12-18 2010-06-23 Aposcience AG Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
EP3502692A1 (en) * 2017-12-20 2019-06-26 Aposcience AG Potency assay for secretomes

Also Published As

Publication number Publication date
KR102996956B1 (ko) 2026-07-27
US20230000910A1 (en) 2023-01-05
CN115023235A (zh) 2022-09-06
CN115023235B (zh) 2026-02-03
EP4081246A1 (en) 2022-11-02
JP2023507518A (ja) 2023-02-22
PL4081246T3 (pl) 2024-10-14
ES2982055T3 (es) 2024-10-14
HUE066648T2 (hu) 2024-08-28
EP3842064A1 (en) 2021-06-30
AU2020415329A1 (en) 2022-06-09
EP4081246B1 (en) 2024-04-10
CA3161094A1 (en) 2021-07-01
JP7675446B2 (ja) 2025-05-13
BR112022011976A2 (pt) 2022-08-30
KR20220119039A (ko) 2022-08-26
WO2021130305A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
EP3897522A4 (en) MICROCAPSULE COMPOSITION
DK3593817T3 (da) Sammensætning til anvendelse til forebyggelse eller undertrykkelse af nærsynethed
DK3501542T3 (da) Esketamin til behandling af depression
DK3600270T3 (da) Forbindelser og sammensætninger til behandling af hæmatologiske lidelser
DK3785733T3 (da) Farmaceutisk sammensætning til behandling af autisme
DK3402499T3 (da) Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes
EP3595653A4 (en) PLINABULIN COMPOSITIONS AND THEIR USE
DK3341355T3 (da) (s)-3-amino-4-(difluormethylenyl)cyclopent-1-en-1-carboxylsyre og tilhørende forbindelser som gaba-aminotransferaseinaktivatorer til behandling af epilepsi, afhængighed og hepatocellulært karcinom
DK3277270T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
DK3504210T3 (da) 7-substituerede sulfonimidoylpurinonforbindelser til behandling og forebyggelse af virusinfektion
SI3347352T1 (sl) Terapevtske spojine uporabne za profilaktično ali terapevtsko zdravljenje okužbe z virusom HIV
IL311256A (en) Methods and uses of microbiome compositions, components, or metabolites for treating neurodegenerative diseases
DK4101454T3 (da) Sammensætninger til behandling af hypertension
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
EP3849527C0 (en) FORMULATIONS OF CYCLOSERINE COMPOUNDS AND THEIR APPLICATIONS
DK3810128T3 (da) Sammensætninger til behandling og/eller forebyggelse af proteinaggregeringssygdomme
DK3318251T3 (da) Sammensætning til forebyggelse eller behandling af fedme eller lipidrelateret metabolisk sygdom
EP3655036C0 (en) COMPOSITIONS FOR THE TREATMENT OF STRESS-RELATED DISORDERS
DK3886799T3 (da) Sammensætninger til behandlingen af hårtab
EP3719032A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF HAIR LOSS
EP3755336A4 (en) COMPOSITION TO PREVENT OR TREAT UVEITIS
EP3493823C0 (en) POSTBIOTIC BASED COMPOUND FOR THE TREATMENT OF OCULAR INFLAMMATION
DK3478713T3 (da) Sammensætninger til behandling af amyloidose
EA201990064A1 (ru) Противомалярийные композиции и варианты их применения